Back to results

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) (THRIVE-AA2)

Primary Purpose

Alopecia Areata

Status

Completed

Phase

Phase 3

Locations

International

Study Type

Interventional

Intervention

CTP-543 matching placebo

CTP-543

About this trial

This is an interventional treatment trial for Alopecia Areata focused on measuring Alopecia, Hair loss, Hair disease, CTP-543

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted.
At least 50% scalp hair loss, as defined by a SALT score ≥50, at Screening and Baseline.
Willing to comply with the study visits and requirements of the study protocol.

Exclusion Criteria:

Treatment with other medications or agents within 1 month of Baseline or during the study that may affect hair regrowth or immune response.
Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or other scalp condition that may interfere with the SALT assessment, or untreated actinic keratosis anywhere on the body at Screening and/or Baseline.
Treatment with systemic immunosuppressive medications within 3 months of Screening or during the study, or biologics within 6 months of Screening or during the study.
Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug.
Clinically significant medical condition, psychiatric disease, or social condition, as determined by the Investigator, that may unfavorably alter the risk-benefit of study participation, adversely affect study compliance, or confound interpretation of study results.

Sites / Locations

Alliance Dermatology & Mohs Center
Johnson Dermatology
Dermatology Research Associates
University of Miami Hospital
Floridian Research Institute LLC
MetroBoston Clinical Partners, LLC
Clinical Research Institute of Michigan, LLC
Hamzavi Dermatology
Galen Research
Vivida Dermatology
The Dermatology Group P.C.
Icahn School of Medicine at Mount Sinai
Columbia University Medical Center - Department of Dermatology
University of Rochester
Dermatologists of Southwest Ohio
Oregon Medical Research
Velocity Clinical Research - Providence
The Skin Wellness Center
North Texas Center for Clinical Research
Elixir Research Group
Progressive Clinical Research
Velocity Clinical Research/Gateway
Velocity Clinical Research/Swinyer-Woseth Dermatology
Jordan Valley Dermatology Center
The Rector and Visitors of the University of Virginia
Care Clinic Ltd.
Medical Arts Health Research Group
Kingsway Clinical Research
North Bay Dermatology Centre
The Centre for Dermatology
Centre de Recherche Saint-Louis
Centre de Recherche Dermatologique du Quebec Metropolitan
Centre Hospitalier Universitaire de Nice - Hôpital Archet 2
Chru de Brest - Hôpital Morvan
Universitaetsklinikum Tübingen
Klinikum Rechts Der Isar, Technische Universität München
Universitätsklinikum Frankfurt Klinik Für Dermatologie, Venerologie Und Allergologie
Fachklinik Bad Bentheim - Dermatologische Studienambulanz
Dermatologische Studienambulanz
University Hospital Muenster
Clinical Research Center for Hair and Skin Science, Dept of Dermatology, Charité Universitätsmedizin Berlin
Universitätsklinikum Erlangen Hautklinik
Pécsi Tudományegyetem Klinikai Központ, Bőr-, Nemikórtani És Onkodermatológiai Klinika
Szte Áok Szent-Györgyi Albert Klinikai Központ Bőrgyógyászati És Allergológiai Klinika
Bugát Pál Kórház
Semmelweis Egyetem, Általános Orvostudományi Kar, Bőr-, Nemikórtani És Bőronkológiai Klinika
Wromedica I. Bielicka, A. Strzalkowska S.C.
Twoja Przychodnia - Centrum Medyczne Nowa Sól
Etg Siedlce
Ot.Co Clinic Klinika Osipowicz & Turkowski Sp. Z O.O.
Rcmed Oddzial Warszawa
Carpe Diem Centrum Medycyny Estetycznej
Etg Warszawa
Twoja Przychodnia - Szczecinskie Centrum Medyczne
Etg Skierniewice
Hospital Del Mar
Hospital Santa Creu I Sant Pau
Hospital Clinic de Barcelona
Hospital Universitario Reina Sofia
Hospital Universitario Ramón Y Cajal - Edificio Consultas Externas
Hospital Doce de Octubre
Hospital Universitario La Paz
Hospital Universitario Infanta Leonor

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Experimental

Arm Label

Placebo

CTP-543 8 mg BID

CTP-543 12 mg BID

Arm Description

Participants received CTP-543 matched placebo tablets, orally, twice daily (BID) for up to 24 weeks.

Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.

Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.

Outcomes

Primary Outcome Measures

Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score ≤20 at Week 24

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

Secondary Outcome Measures

Percentage of Responders on the Hair Satisfaction Participants Reported Outcome (SPRO) Scale at Weeks 12, 16, 20, and 24

SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. Responders were defined as participants with responses of "satisfied" or "very satisfied".

Percentage of Participants Achieving an Absolute SALT Score of ≤20 at Weeks 4, 8, 12, 16, and 20

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Relative change (percent change) to baseline is calculated as: 100 x ([post-baseline SALT score - baseline SALT score]/baseline SALT score).

Percentage of Responders Assessed Using the Clinician Global Impression of Improvement (CGI-I) at Weeks 12, 16, 20, and 24

The CGI-I is a questionnaire that asks the clinician to evaluate the improvement or worsening of the participant's alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved).

Percentage of Responders Assessed Using the Patient Global Impression of Improvement (PGI-I) at Weeks 12, 16, 20, and 24

The PGI-I is a self-administered questionnaire that asks the participant to evaluate the improvement or worsening of their alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved).

Change in the Clinician Global Impression of Severity (CGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24

The CGI-S is a questionnaire that asks the clinician to evaluate the symptom severity of the participant's alopecia areata at the time of assessment. The symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.

Change in the Patient Global Impression of Severity (PGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24

The PGI-S is a self-administered questionnaire that asks the participant to evaluate the symptom severity of their alopecia areata at the time of assessment. Symptom severity was rated on a scale ranging from 1 to 7, where 1= normal, no hair loss; 2= borderline hair loss; 3= mild hair loss; 4= moderate hair loss; 5= marked hair loss; 6= severe hair loss; 7= among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.

Percentage of Participants Achieving at Least a 75% and 90% Relative Reduction in SALT Score From Baseline at Weeks 12 and 24

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Percentage of participants achieving at least a 75% and 90% relative reduction in SALT score from baseline at Weeks 12 and 24 are reported.

Change in the Brigham Eyebrow Tool for Alopecia (BETA) Scores From Baseline at Weeks 12 and 24

BETA is a clinician-rated scale that assesses the total eyebrow hair present. The BETA score is calculated based on hair density and surface area of each individual eyebrow of the participant, ranging from 0 to 3, where 0= no eyebrow, 1= minimal eyebrow, 2= moderate eyebrow, and 3= normal eyebrow. The BETA score is the sum of the right and left eyebrow scores, ranging from 0 to 6. Higher scores indicate less hair loss of eyebrows. A positive change from baseline indicates less hair loss of eyebrows.

Change in the Brigham Eyelash Tool for Alopecia (BELA) Scores From Baseline at Weeks 12 and 24

BELA is a clinician-rated scale that assesses the total eyelash hair present. The BELA is calculated based on distribution and grade values, ranging from 0 (no eyelashes) to 3 (full eyelashes). The BELA score is the sum of the individual scores for the left and right eyes, ranging from 0 to 6. Higher scores indicate less hair loss of eyelashes. A positive change from baseline indicates less hair loss of eyelashes.

Change in the SPRO Scale From Baseline at Weeks 12, 16, 20, and 24

SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. Higher scores indicate the greater hair dissatisfaction. A negative change from baseline indicate the greater hair satisfaction.

Percentage of Participants Achieving a ≥2-point Change From Baseline in the SPRO Scale at Weeks 12, 16, 20, and 24

SPRO is a questionnaire answered by the participants and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied.

Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24

The QPRO questionnaire provides additional details on key attributes of hair and helps provide context to the SPRO response. The individual items of QPRO are: Satisfied thickness hair coverage; Satisfied evenness hair coverage; How satisfied with your eyebrows; How satisfied with your eyelashes, scored on a scale ranging from 1 to 5 where 1=very satisfied, 2=satisfied, 3=neither satisfied nor dissatisfied, 4=dissatisfied, 5=very dissatisfied. Higher scores indicate the greater dissatisfaction on hair quality. A negative change from baseline indicate the greater satisfaction on hair quality.

Change in the Anxiety and Depression Scale Scores of the Hospital Anxiety and Depression Scale (HADS) From Baseline at Week 24

HADS is questionnaire designed to assess anxiety and depression symptoms which is completed by participants. The questionnaire is comprised of two separate scales with a total of 14 items: A 7-item scale related to anxiety and 7-item scale related to depression. Each item within both scales is scored using a 4-point scale, ranging from 0 to 3 and the total scores in each scale can range from 0 to 21. Separate scores were created for anxiety and depression. A score between 0-7 is considered normal, 8-10 is mild, 11-14 is moderate, and >14 is severe anxiety or depression. Higher scores indicate greater severity. A negative change from baseline indicates less severity.

Percentage of Participants Achieving an Absolute SALT Score of ≤10 at Week 24

SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).

Full Information

NCT ID

NCT04797650

First Posted

March 10, 2021

Last Updated

June 30, 2023

Sponsor

Concert Pharmaceuticals

1. Study Identification

Unique Protocol Identification Number

NCT04797650

Brief Title

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)

Acronym

THRIVE-AA2

Official Title

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Study Type

Interventional

2. Study Status

Record Verification Date

June 2023

Overall Recruitment Status

Completed

Study Start Date

June 10, 2021 (Actual)

Primary Completion Date

June 8, 2022 (Actual)

Study Completion Date

June 29, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Concert Pharmaceuticals

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Alopecia Areata

Keywords

Alopecia, Hair loss, Hair disease, CTP-543

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

517 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Placebo

Arm Type

Placebo Comparator

Arm Description

Participants received CTP-543 matched placebo tablets, orally, twice daily (BID) for up to 24 weeks.

Arm Title

CTP-543 8 mg BID

Arm Type

Experimental

Arm Description

Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.

Arm Title

CTP-543 12 mg BID

Arm Type

Experimental

Arm Description

Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.

Intervention Type

Drug

Intervention Name(s)

CTP-543 matching placebo

Intervention Description

Administered as tablets.

Intervention Type

Drug

Intervention Name(s)

CTP-543

Intervention Description

Administered as tablets.

Primary Outcome Measure Information:

Title

Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score ≤20 at Week 24

Description

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

Time Frame

Week 24

Secondary Outcome Measure Information:

Title

Percentage of Responders on the Hair Satisfaction Participants Reported Outcome (SPRO) Scale at Weeks 12, 16, 20, and 24

Description

Time Frame

Weeks 12, 16, 20, and 24

Title

Percentage of Participants Achieving an Absolute SALT Score of ≤20 at Weeks 4, 8, 12, 16, and 20

Description

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

Time Frame

Weeks 4, 8, 12, 16, and 20

Title

Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24

Description

Time Frame

Baseline, Weeks 4, 8, 12, 16, 20, and 24

Title

Percentage of Responders Assessed Using the Clinician Global Impression of Improvement (CGI-I) at Weeks 12, 16, 20, and 24

Description

Time Frame

Weeks 12, 16, 20, and 24

Title

Percentage of Responders Assessed Using the Patient Global Impression of Improvement (PGI-I) at Weeks 12, 16, 20, and 24

Description

Time Frame

Weeks 12, 16, 20, and 24

Title

Change in the Clinician Global Impression of Severity (CGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24

Description

Time Frame

Baseline, Weeks 12, 16, 20, and 24

Title

Change in the Patient Global Impression of Severity (PGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24

Description

Time Frame

Baseline, Weeks 12, 16, 20, and 24

Title

Percentage of Participants Achieving at Least a 75% and 90% Relative Reduction in SALT Score From Baseline at Weeks 12 and 24

Description

Time Frame

Baseline, Weeks 12, and 24

Title

Change in the Brigham Eyebrow Tool for Alopecia (BETA) Scores From Baseline at Weeks 12 and 24

Description

Time Frame

Baseline, Weeks 12, and 24

Title

Change in the Brigham Eyelash Tool for Alopecia (BELA) Scores From Baseline at Weeks 12 and 24

Description

Time Frame

Baseline, Weeks 12, and 24

Title

Change in the SPRO Scale From Baseline at Weeks 12, 16, 20, and 24

Description

SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. Higher scores indicate the greater hair dissatisfaction. A negative change from baseline indicate the greater hair satisfaction.

Time Frame

Baseline, Weeks 12, 16, 20 and 24

Title

Percentage of Participants Achieving a ≥2-point Change From Baseline in the SPRO Scale at Weeks 12, 16, 20, and 24

Description

Time Frame

Weeks 12, 16, 20, and 24

Title

Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24

Description

Time Frame

Baseline, Weeks 12, 16, 20, and 24

Title

Change in the Anxiety and Depression Scale Scores of the Hospital Anxiety and Depression Scale (HADS) From Baseline at Week 24

Description

Time Frame

Baseline and Week 24

Title

Percentage of Participants Achieving an Absolute SALT Score of ≤10 at Week 24

Description

SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).

Time Frame

Week 24

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

65 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted. At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50, at Screening and Baseline. Willing to comply with the study visits and requirements of the study protocol. Exclusion Criteria: Treatment with other medications or agents within 1 month of Baseline or during the study that may affect hair regrowth or immune response. Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or other scalp condition that may interfere with the SALT assessment, or untreated actinic keratosis anywhere on the body at Screening and/or Baseline. Treatment with systemic immunosuppressive medications within 3 months of Screening or during the study, or biologics within 6 months of Screening or during the study. Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug. Clinically significant medical condition, psychiatric disease, or social condition, as determined by the Investigator, that may unfavorably alter the risk-benefit of study participation, adversely affect study compliance, or confound interpretation of study results.

Facility Information:

Facility Name

Alliance Dermatology & Mohs Center

City

Phoenix

State/Province

Arizona

ZIP/Postal Code

85032

Country

United States

Facility Name

Johnson Dermatology

City

Fort Smith

State/Province

Arkansas

ZIP/Postal Code

72916

Country

United States

Facility Name

Dermatology Research Associates

City

Los Angeles

State/Province

California

ZIP/Postal Code

90045

Country

United States

Facility Name

University of Miami Hospital

City

Miami

State/Province

Florida

ZIP/Postal Code

33124

Country

United States

Facility Name

Floridian Research Institute LLC

City

Miami

State/Province

Florida

ZIP/Postal Code

33145

Country

United States

Facility Name

MetroBoston Clinical Partners, LLC

City

Brighton

State/Province

Massachusetts

ZIP/Postal Code

02135

Country

United States

Facility Name

Clinical Research Institute of Michigan, LLC

City

Chesterfield

State/Province

Michigan

ZIP/Postal Code

48087

Country

United States

Facility Name

Hamzavi Dermatology

City

Fort Gratiot

State/Province

Michigan

ZIP/Postal Code

48059

Country

United States

Facility Name

Galen Research

City

Chesterfield

State/Province

Missouri

ZIP/Postal Code

63005

Country

United States

Facility Name

Vivida Dermatology

City

Las Vegas

State/Province

Nevada

ZIP/Postal Code

89148

Country

United States

Facility Name

The Dermatology Group P.C.

City

Verona

State/Province

New Jersey

ZIP/Postal Code

07044

Country

United States

Facility Name

Icahn School of Medicine at Mount Sinai

City

New York

State/Province

New York

ZIP/Postal Code

10029

Country

United States

Facility Name

Columbia University Medical Center - Department of Dermatology

City

New York

State/Province

New York

ZIP/Postal Code

10032

Country

United States

Facility Name

University of Rochester

City

Rochester

State/Province

New York

ZIP/Postal Code

14642

Country

United States

Facility Name

Dermatologists of Southwest Ohio

City

Mason

State/Province

Ohio

ZIP/Postal Code

45040

Country

United States

Facility Name

Oregon Medical Research

City

Portland

State/Province

Oregon

ZIP/Postal Code

97223

Country

United States

Facility Name

Velocity Clinical Research - Providence

City

Warwick

State/Province

Rhode Island

ZIP/Postal Code

02886

Country

United States

Facility Name

The Skin Wellness Center

City

Knoxville

State/Province

Tennessee

ZIP/Postal Code

37922

Country

United States

Facility Name

North Texas Center for Clinical Research

City

Frisco

State/Province

Texas

ZIP/Postal Code

75034

Country

United States

Facility Name

Elixir Research Group

City

Houston

State/Province

Texas

ZIP/Postal Code

77077

Country

United States

Facility Name

Progressive Clinical Research

City

San Antonio

State/Province

Texas

ZIP/Postal Code

78213

Country

United States

Facility Name

Velocity Clinical Research/Gateway

City

Salt Lake City

State/Province

Utah

ZIP/Postal Code

84101

Country

United States

Facility Name

Velocity Clinical Research/Swinyer-Woseth Dermatology

City

Salt Lake City

State/Province

Utah

ZIP/Postal Code

84117

Country

United States

Facility Name

Jordan Valley Dermatology Center

City

South Jordan

State/Province

Utah

ZIP/Postal Code

84095

Country

United States

Facility Name

The Rector and Visitors of the University of Virginia

City

Charlottesville

State/Province

Virginia

ZIP/Postal Code

22903

Country

United States

Facility Name

Care Clinic Ltd.

City

Red Deer

State/Province

Alberta

ZIP/Postal Code

T4N6V7

Country

Canada

Facility Name

Medical Arts Health Research Group

City

Kelowna

State/Province

British Columbia

ZIP/Postal Code

V1Y 4N7

Country

Canada

Facility Name

Kingsway Clinical Research

City

Etobicoke

State/Province

Ontario

ZIP/Postal Code

M8X1Y9

Country

Canada

Facility Name

North Bay Dermatology Centre

City

North Bay

State/Province

Ontario

ZIP/Postal Code

P1B 3Z7

Country

Canada

Facility Name

The Centre for Dermatology

City

Richmond Hill

State/Province

Ontario

ZIP/Postal Code

L4B1A5

Country

Canada

Facility Name

Centre de Recherche Saint-Louis

City

Quebec

ZIP/Postal Code

G1W4R4

Country

Canada

Facility Name

Centre de Recherche Dermatologique du Quebec Metropolitan

City

Quebec

ZIP/Postal Code

L4B1A5

Country

Canada

Facility Name

Centre Hospitalier Universitaire de Nice - Hôpital Archet 2

City

Nice

State/Province

Alpes-maritimes

ZIP/Postal Code

06202 CEDEX 3

Country

France

Facility Name

Chru de Brest - Hôpital Morvan

City

Brest

State/Province

Finestère

ZIP/Postal Code

29609 CEDEX

Country

France

Facility Name

Universitaetsklinikum Tübingen

City

Tübingen

State/Province

Baden-württemberg

ZIP/Postal Code

72076

Country

Germany

Facility Name

Klinikum Rechts Der Isar, Technische Universität München

City

Munich

State/Province

Bayern

ZIP/Postal Code

80802

Country

Germany

Facility Name

Universitätsklinikum Frankfurt Klinik Für Dermatologie, Venerologie Und Allergologie

City

Frankfurt am main

State/Province

Hessen

ZIP/Postal Code

60590

Country

Germany

Facility Name

Fachklinik Bad Bentheim - Dermatologische Studienambulanz

City

Bad Bentheim

State/Province

Niedersachsen

ZIP/Postal Code

48455

Country

Germany

Facility Name

Dermatologische Studienambulanz

City

Bochum

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

44791

Country

Germany

Facility Name

University Hospital Muenster

City

Münster

State/Province

Nordrhein-westfalen

ZIP/Postal Code

48149

Country

Germany

Facility Name

Clinical Research Center for Hair and Skin Science, Dept of Dermatology, Charité Universitätsmedizin Berlin

City

Berlin

ZIP/Postal Code

10117

Country

Germany

Facility Name

Universitätsklinikum Erlangen Hautklinik

City

Erlangen

ZIP/Postal Code

91054

Country

Germany

Facility Name

Pécsi Tudományegyetem Klinikai Központ, Bőr-, Nemikórtani És Onkodermatológiai Klinika

City

Pécs

State/Province

Baranya

ZIP/Postal Code

7632

Country

Hungary

Facility Name

Szte Áok Szent-Györgyi Albert Klinikai Központ Bőrgyógyászati És Allergológiai Klinika

City

Szeged

State/Province

Csongrád-csanád

ZIP/Postal Code

6720

Country

Hungary

Facility Name

Bugát Pál Kórház

City

Gyöngyös

State/Province

Heves

ZIP/Postal Code

3200

Country

Hungary

Facility Name

Semmelweis Egyetem, Általános Orvostudományi Kar, Bőr-, Nemikórtani És Bőronkológiai Klinika

City

Budapest

State/Province

Pest

ZIP/Postal Code

1085

Country

Hungary

Facility Name

Wromedica I. Bielicka, A. Strzalkowska S.C.

City

Wrocław

State/Province

Dolnośląskie

ZIP/Postal Code

50-685

Country

Poland

Facility Name

Twoja Przychodnia - Centrum Medyczne Nowa Sól

City

Nowa Sól

State/Province

Lubuskie

ZIP/Postal Code

67-100

Country

Poland

Facility Name

Etg Siedlce

City

Siedlce

State/Province

Mazowieckie

ZIP/Postal Code

08-110

Country

Poland

Facility Name

Ot.Co Clinic Klinika Osipowicz & Turkowski Sp. Z O.O.

City

Warszawa

State/Province

Mazowieckie

ZIP/Postal Code

00-716

Country

Poland

Facility Name

Rcmed Oddzial Warszawa

City

Warszawa

State/Province

Mazowieckie

ZIP/Postal Code

00-892

Country

Poland

Facility Name

Carpe Diem Centrum Medycyny Estetycznej

City

Warszawa

State/Province

Mazowieckie

ZIP/Postal Code

02-664

Country

Poland

Facility Name

Etg Warszawa

City

Warszawa

State/Province

Mazowieckie

ZIP/Postal Code

02-793

Country

Poland

Facility Name

Twoja Przychodnia - Szczecinskie Centrum Medyczne

City

Szczecin

ZIP/Postal Code

71-434

Country

Poland

Facility Name

Etg Skierniewice

City

Skierniewice

State/Province

Łódzkie

ZIP/Postal Code

96-100

Country

Poland

Facility Name

Hospital Del Mar

City

Barcelona

State/Province

Cataluña

ZIP/Postal Code

08001

Country

Spain

Facility Name

Hospital Santa Creu I Sant Pau

City

Barcelona

State/Province

Cataluña

ZIP/Postal Code

08041

Country

Spain

Facility Name

Hospital Clinic de Barcelona

City

Barcelona

ZIP/Postal Code

08036

Country

Spain

Facility Name

Hospital Universitario Reina Sofia

City

Córdoba

ZIP/Postal Code

14004

Country

Spain

Facility Name

Hospital Universitario Ramón Y Cajal - Edificio Consultas Externas

City

Madrid

ZIP/Postal Code

28034

Country

Spain

Facility Name

Hospital Doce de Octubre

City

Madrid

ZIP/Postal Code

28041

Country

Spain

Facility Name

Hospital Universitario La Paz

City

Madrid

ZIP/Postal Code

28046

Country

Spain

Facility Name

Hospital Universitario Infanta Leonor

City

Madrid

ZIP/Postal Code

28081

Country

Spain

12. IPD Sharing Statement

Plan to Share IPD

Learn more about this trial

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)

We'll reach out to this number within 24 hrs